Lepodisiran reduces oxidised phospholipids associated with Lp(a)

Lepodisiran produces dose dependent reductions in oxidised phospholipids (OxPL) associated with Lp(a), with reductions most consistent at the 400 mg dose, and correlating closely with those seen in Lp(a) levels. These post hoc findings from the Phase 2 ALPACA trial in participants with elevated Lp(a) levels were presented by Professor Steven Nissen, Cleveland Clinic, Ohio, USA, at a Late Breaking Science Session at ESC 2026 congress, and published simultaneously in the Journal of the American College of Cardiology.^1,2